Neurocrine Biosciences (NBIX)

• Market cap: $11.2B
• 1 day: -1.39%
• 5 days: -0.20%
• 1 month: -5.31%
• 3 months: -17.98%
• 6 months: -2.43%
• Year to date: -18.45%
• 1 year: -18.49%
• 5 years: 22.74%
• 10 years: 170.70%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Employees: 1,800

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 108 | Existing positions closed: 72

20% more funds holding in top 10

Funds holding in top 10: 10 [Q3] → 12 (+2) [Q4]

19% more capital invested

Capital invested by funds: $10.8B [Q3] → $12.9B (+$2.03B) [Q4]

4% more funds holding

Funds holding: 564 [Q3] → 585 (+21) [Q4]

9% more call options, than puts

Call options by funds: $48M | Put options by funds: $44.2M

4% more repeat investments, than reductions

Existing positions increased: 213 | Existing positions reduced: 204

0.01% more ownership

Funds ownership: 93.2% [Q3] → 93.21% (+0.01%) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $147 31% upside
• Avg. target: $166 48% upside
• High target: $185 65% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

JP Morgan Anupam Rama 28% 1-year accuracy 17 / 61 met price target	64% upside $184	Overweight Maintained	26 Mar 2025
Morgan Stanley Jeffrey Hung 37% 1-year accuracy 10 / 27 met price target	33% upside $150	Overweight Assumed	7 Mar 2025
HC Wainwright & Co. Andrew Fein 34% 1-year accuracy 121 / 355 met price target	65% upside $185	Buy Reiterated	24 Feb 2025
Guggenheim Yatin Suneja 31% 1-year accuracy 10 / 32 met price target	45% upside $163	Buy Maintained	10 Feb 2025
RBC Capital Brian Abrahams 19% 1-year accuracy 13 / 70 met price target	32% upside $148	Sector Perform Maintained	7 Feb 2025